Fig. 5.
Effects of RAR and RXR-receptor–selective retinoids or both on TGase II activity in RPMI 8226 cells. Cells were treated for 48 hours with 10−7 mol/L atRA, varying doses of CD367 (A), CD2425 (B), and their combination (C), in defined medium for 7 hours, and then in 3% FCS-supplemented medium.
